Clinical trial
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase)…
NCT00271765 · Inotek Pharmaceuticals Corporation, Industry · Completed
Key facts
| NCT number | NCT00271765 |
|---|---|
| Title | A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention |
| Official title | A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous… |
| Lead sponsor | Inotek Pharmaceuticals Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myocardial Infarction |
| Intervention type | Drug |
| Interventions | INO-1001 |
| Enrollment | 40 |
| Start date | Jan 1, 2004 |
| Completion | Jun 1, 2006 |
| First posted | Jan 4, 2006 |
| Last update posted | Nov 29, 2006 |
| Countries | Israel, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: